Silence Therapeutics develops siRNA-based medicines targeting genetic diseases, focusing on hematology, cardiovascular disease, and rare diseases, based on its mRNAi GOLD™ platform.

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

COM:SILENCE-THERAPEUTICS

Silence Therapeutics

Last Close

540.00

01/01 00:00

Volume Today

913.53K

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics